Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-finding study of brexpiprazole in schizophrenia
NCT01451164Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Oct 2011
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of brexpiprazole orally disintegrating tablet in schizophrenia (4 arms), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoint: Positive and Negative Syndrome Scale Total Score at 6 weeks. Started Oct 2011; status: completed.
02
Drugs
brexpiprazole orally disintegrating tablet
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT01451164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01451164.